公开(公告)号：US11377503B2

公开(公告)日：2022-07-05

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US12195555B2

公开(公告)日：2025-01-14

申请号：US18469947

申请日：2023-09-19

Applicant: SANOFI ,  INNATE PHARMA

Inventor： Nicolas Gourdin ,  Laurent Gauthier ,  Alexandre Tang ,  Marielle Chiron ,  Angela Virone-Oddos ,  Alessandro Masiero ,  Jochen Beninga ,  Ingo Focken ,  Sambasiva Rao ,  Yanfeng Zhou ,  Leila Sevigny

IPC: C07K16/46 ,  A61P35/00 ,  C12N15/63

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

公开(公告)号：US20200024357A1

公开(公告)日：2020-01-23

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11578136B2

公开(公告)日：2023-02-14

申请号：US16477506

申请日：2018-03-16

Applicant: INNATE PHARMA ,  OREGA BIOTECH

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US20230025732A1

公开(公告)日：2023-01-26

申请号：US17855510

申请日：2022-06-30

Applicant: Innate Pharma ,  Orega Biotech

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US12202907B2

公开(公告)日：2025-01-21

申请号：US17855510

申请日：2022-06-30

Applicant: Innate Pharma ,  Orega Biotech

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US20190218308A1

公开(公告)日：2019-07-18

申请号：US16370726

申请日：2019-03-29

Applicant: INNATE PHARMA

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/40 ,  A61P35/00 ,  G01N33/574 ,  C07K16/28 ,  A61K9/00

CPC classification number: C07K16/2896 ,  A61K39/001154 ,  A61K2039/507 ,  A61K2039/545 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/92 ,  C12N9/14

Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.

公开(公告)号：US20230340143A1

公开(公告)日：2023-10-26

申请号：US18168522

申请日：2023-02-13

Applicant: Innate Pharma ,  OREGA BIOTECH

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  G01N33/57492 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11130817B2

公开(公告)日：2021-09-28

申请号：US15767661

申请日：2016-10-11

Applicant: INNATE PHARMA ,  CENTRE LEON BERARD

Inventor： Christophe Caux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Christine Menetrier-Caux ,  Carine Paturel ,  Ivan Perrot

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00

Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.

公开(公告)号：US20190389961A1

公开(公告)日：2019-12-26

申请号：US16477506

申请日：2018-03-16

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.